| 0 | ～ 田 | 0 | 价格 = | 涨跌幅 ◆ | | --- | --- | --- | --- | --- | | 道琼斯指数 | | | 47861.75 | -0.19% | | .DJI | | | | | | 标普500指数 | | | 6863.48 | -0.10% | | .SPX | | | | | | 纳斯达克综合指数 | | | 23590.61 | +0.05% | | .IXIC | | | | | 又有个股暴涨。 当地时间12月8日，美股三大股指早盘涨跌不一，截至发稿，道指跌0.19%，标普500指数跌0.1%，纳指微涨0.05%。 消息面上，本周美联储联邦公开市场委员会（FOMC）将公布利率决议。芝商所"美联储观察"工具显示，市场预计降息25个基点的概率为89.6%，按兵不 动的概率仅略高于10%。 白宫经济顾问哈塞特就美联储发表看法称，应该继续降低利率。关于利率应降至多低的问题，他表示必须密切关注数据情况。他还表示，若现在就公布未 来6个月的利率承诺，将是不负责任的行为。 野村发布最新报告称，预计美联储12月还是会选择降息25个基点。野村策略师表示："对美联储中间派 ...

Core Viewpoint - The article discusses the recent fluctuations in the U.S. stock market, focusing on the anticipated interest rate decisions by the Federal Reserve and the significant stock price movements of certain companies in the biotechnology sector. Group 1: Market Overview - As of December 8, U.S. stock indices showed mixed performance, with the Dow Jones down 0.19%, S&P 500 down 0.1%, and Nasdaq up 0.05% [2][3]. - The market is anticipating a 25 basis point rate cut by the Federal Reserve, with a probability of 89.6% according to the CME FedWatch Tool [2][4]. Group 2: Federal Reserve Insights - Nomura's report suggests that the Federal Reserve is likely to cut rates by 25 basis points in December, with some hawkish members expected to oppose this decision [4]. - Morgan Stanley has revised its prediction, now expecting a rate cut after the December 9-10 policy meeting, previously having delayed this expectation to 2026 due to strong employment data [4]. Group 3: Stock Performance - Wave Life Sciences saw a significant stock increase of 106.19% after announcing positive mid-stage trial results for its obesity treatment WVE-007, which showed improvements in body composition [5][7]. - Structure Therapeutics experienced a stock surge of 121.99%, attributed to a mid-stage clinical trial showing an 11.3% reduction in body weight for its obesity treatment candidate [8].